The HLA Typing Market is expected to grow at a CAGR of 5.6% from 2022 to 2029 to reach $1.9 billion by 2029, according to Meticulous Research. The HLA Typing Market includes consumables, instruments, software & services. The growth in HLA typing market is mainly attributed to the increasing number of organ transplantation procedures and technological advancements in molecular assays for HLA typing. Moreover, increasing awareness regarding the importance of organ donation is expected to create market growth opportunities.
Here are the top 10 companies operating in the HLA Typing Market
Becton, Dickinson and Company (BD) (U.S.)
Founded in 1897 and headquartered in New Jersey, U.S. Becton, Dickinson and Company (BD) is engaged in developing, manufacturing, and selling a broad line of medical devices, supplies, laboratory equipment, and diagnostic products. BD operates through three reportable business segments, namely, BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences segment consists of two organizational units: Integrated Diagnostic Solutions and Biosciences. The company operates in the HLA typing market through its Biosciences unit. Furthermore, it offers HLA antibodies and immunofluorescence test kits for detecting HLA antigens.
The company has manufacturing facilities outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, and the U.K.
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo is a biotechnology company engaged in life sciences research, improving patient diagnostics, and increasing laboratory productivity. The company operates through four business segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Specialty Diagnostics business segment is divided into five primary businesses: Clinical Diagnostics, Immuno Diagnostics, Microbiology, Transplant Diagnostics, and Healthcare Market Channel. The company operates in the HLA typing market through its Transplant Diagnostics business. It offers HLA typing and antibody detection assays based on serological, molecular, and enzyme-linked immunosorbent assays (ELISA), flow cytometry, and multiplexing technologies in the HLA typing market.
Thermo Fisher has a presence in approximately 50 countries outside the U.S. The company has major manufacturing and distribution facilities in the U.S., Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, and the U.K.
Illumina, Inc. (U.S.)
Founded in 1998 and headquartered in California, U.S., Illumina develops, manufactures, and markets life sciences tools and integrated systems for functional and variational analysis of genes. The company provides array and sequence-based solutions such as integrated sequencing and microarray systems, consumables, and genetic and genomic analysis tools. The company operates in two reportable business segments, namely, Core Illumina and GRAIL. It operates in the HLA typing market through the Core Illumina business segment, for which it offers Next Generation Sequencing (NGS) based assays and HLA analysis software for HLA typing market.
Illumina operates in around 28 countries globally and has commercial offices in the U.S., Australia, Germany, China, France, Japan, Brazil, the Netherlands, the U.K., Singapore, and South Korea. The company has a geographical presence across Belgium, Netherlands, Norway, Denmark, France, Israel, Italy, Germany, Sweden, Belgium, Brazil, the U.K., Japan, India, China, Norway, New Zealand, Russia, Singapore, and Switzerland through its subsidiaries.
CareDx, Inc. (U.S.)
Founded in 1998 and headquartered in California, U.S., CareDx is involved in discovering, developing, and commercializing diagnostics solutions for transplant patients and caregivers. The company offers its products through three business segments, namely, Testing Services, Products, and Patient and Digital Solutions. The company provides HLA typing solutions through all these business segments. In the testing services, the company develops and provides diagnostic surveillance services for solid organ transplant recipients, hematopoietic stem cell transplant recipients and recipients of engineered cell therapies. The company develops, manufactures, and markets products to enable transplantation. Through the Patient and Digital Solutions segment, the company provides digital solutions related to transplantation.
The company has a global presence across all the major regions, including North America, Asia-Pacific, the Middle East, Europe, Central America, and South America. Its manufacturing facilities and sales offices are in Sweden and Australia and the U.S. and Australia, respectively. A strong distribution network enables the company to sell its products in Germany, the U.K., New Zealand, Sweden, Austria, Belgium, Netherlands, Australia, Canada, France, and Turkey. Some of the major subsidiaries of the company are CareDx International AB (Sweden), CareDx AB (Sweden), and CareDx GmbH (Austria).
Genome Diagnostics B.V. (GenDx) (Netherlands)
Founded in 2005 and headquartered in Utrecht, Netherlands, GenDx is a molecular diagnostics and HLA typing company that offers and develops diagnostics tests, services, software, and educational products. The company offers products in HLA typing, chimerism monitoring, next-generation sequencing-killer cell immunoglobulin-like receptor typing (NGS-KIR), NGSmajor histocompatibility complex (MHC) class I polypeptide-related sequence A typing (MICA), and MHC class I polypeptide related sequence B (MICB) typing. Additionally, the company also provides custom lab services.
GenDx operates in the HLA typing market by offering reagents, software, and consumables and offers sanger and NGS-based HLA typing products. The company has an indirect presence globally through its distributors in Algeria, Morocco, South Africa, Tunisia, China, Hong Kong, India, Japan, Denmark, Bahrain, Iraq, Israel, Jordan, Canada, the U.S., Brazil, and Colombia; and manufacturing and R&D sites in the Netherlands.
Meticulous Research in its latest publication on HLA Typing Market has predicted the growth of 5.6% during the forecast year 2022-2029
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in the U.S., Bio-Rad is a company engaged in manufacturing and distributing life science research and clinical diagnostics products and systems. The company has two reportable business segments, namely, Life Science and Clinical Diagnostics. Bio-Rad operates in the HLA typing market through its Clinical Diagnostics business segment. The segment designs, manufactures, and sells test systems, informatics systems, test kits, and specialized quality controls for hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Bio-Rad has a presence in over 36 countries outside the U.S. through subsidiaries. The company’s principal manufacturing and research sites are in the U.S., Singapore, the U.K., France, Belgium, Switzerland, and Germany. Some of the subsidiaries of the company are Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories GmbH (Germany), Bio-Rad Services (France), Bio-Rad Laboratories Limited (U.K.), and Bio-Rad Laboratories, S.A (Spain).
Immucor Inc. (U.S.)
Founded in 1982 and headquartered in Georgia, U.S., Immucor Inc. provides transfusion and transplantation diagnostic products. Additionally, the company offers a range of products in the Transfusion, Transplant, and Coagulation segments. Its HLA typing products, such as software and sequencing kits, are offered through its Transplant segment.
In addition to HLA typing, the company’s Transplant segment also offers antibody products and analyzers. The company serves HLA clinical labs, research labs, and registry labs by offering HLA typing products. Immucor has a direct presence through offices and sales representatives across Africa, Australia, the U.S., Asia, Europe, and Asia.
TBG Diagnostics Limited (TDL) (Australia)
Founded in 1989 and headquartered in Queensland, Australia, TDL is a molecular diagnostics company that develops and manufactures diagnostics kits, instruments, and services. The company provides HLA typing solutions such as HLA sequence-specific primer (SSP) typing kits, HLA Sequence-based typing (SBT) kits, and HLA real-time PCR typing kits through its Reagents segment. Furthermore, TDL has a molecular typing laboratory that provides HLA typing services certified by ASHI (American Society of Histocompatibility and Immunology). The company develops in-vitro diagnostics (IVD) products for HLA genotyping and the detection of autoimmune diseases for hospitals, reference laboratories, and blood centers.
The R&D facilities of TDL are based in the U.S., China, and Taiwan. The company manufactures products in its certified facilities in China. Some of its subsidiaries operating in the HLA typing market are TBG Inc. (U.S.), TBG Biotechnology Corp. (Taiwan), Texas Biogene Inc. (U.S.), and TBG Biotechnology Corp. (Xiamen).
BAG Diagnostics GmbH (Germany)
Founded in 1947 and headquartered in Hesse, Germany, BAG Diagnostics offers HLA and blood diagnostics. The company offers transplant diagnostics, transfusion diagnostics, human genetics, infectiology, interpretation software, and automation products. Through its Transplant Diagnostics segment, BAG operates in the HLA typing market by providing testing, reagent kits, RT-PCR typing kits, and KIR SSP typing kits.
The company has an indirect presence through its distributors in Argentina, Austria, Canada, Denmark, France, Great Britain, Greece, Hungary, Iceland, India, Italy, Mexico, Norway, South Africa, Spain, Sweden, and Taiwan.
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN is a provider of samples and assays for the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company’s assays and samples are used for molecular diagnostics, applied testing, and academic & pharmaceutical research. It offers nearly 500 products comprising kits, instruments, and bioinformatics solutions. QIAGEN offers its products to customer groups operating in molecular diagnostics and life sciences areas. Additionally, the company offers products through five major product groups: Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, and Other. QIAGEN offers kits, systems, and software through these segments in the HLA typing market.
The company operates in around 26 countries, including the U.S., Canada, Mexico, Brazil, Africa, UAE, India, Egypt, Turkey, Russia, Spain, France, Germany, the U.K., Denmark, Sweden, Basel, Italy, China, Thailand, India, Malaysia, Australia, Japan, South Korea, and the Philippines, through its subsidiaries. Some of the major subsidiaries of the company are QIAGEN GmbH (Germany), NeuMoDx Molecular, Inc (U.S.), Exiqon A/S (Denmark), SABiosciences Corporation (China), and QIAGEN Sciences, Inc. (U.S.). The manufacturing and R&D facilities of the company are located in Germany, the U.S., the U.K., Spain, and China. Moreover, the company has a strong distribution network in over 60 countries worldwide.
Authoritative Research on the HLA Typing Market – Global Opportunity Analysis and Industry Forecast (2022-2029)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.